
The National Institute for Bioprocessing Research and Training (NIBRT) recently welcomed a delegation from the European Medicines Agency’s (EMA) Committee for Advanced Therapies (CAT) to its Dublin facility, where it showcased Ireland’s growing capabilities in advanced therapy development.
The committee plays a central role in the European regulatory framework for advanced therapy medicinal products (ATMPs), evaluating their quality, safety and efficacy and contributing to scientific guidance as the field evolves.
While the visit highlighted NIBRT’s research and training activities, it also provided a timely opportunity to consider the wider developments shaping Ireland’s advanced therapies ecosystem.
Manufacturing From the Outset
Among the capabilities presented to the delegation was CONCEPT, NIBRT’s core facility for early-stage biotherapy development, which supports academic and industry researchers in translating scientific concepts into physical products.
Through optimised cell lines, research-grade materials and process development expertise, CONCEPT addresses one of the key challenges facing advanced therapies: manufacturability.
Integrating manufacturing considerations from an early stage is particularly important for ATMPs, where the ability to produce therapies consistently and in accordance with required quality standards is fundamental to their successful development and regulatory approval.
Building Beyond Research
The EMA visit comes at a time of significant investment in Ireland’s advanced therapies research and innovation infrastructure, including the recent establishment of Rinn Advanced Therapies, a new Research Ireland centre focused on developing and manufacturing personalised cellular immune therapies.
Led by NIBRT Principal Investigator Professor Sakis Mantalaris, the centre brings together academic, clinical and industry expertise, with the ambition of delivering Ireland’s first cellular immune therapy.
Together with initiatives such as CONCEPT, Rinn reflects Ireland’s growing capabilities across early-stage development, manufacturing innovation and clinical translation.
From Innovation to Patients
As Ireland’s advanced therapies ecosystem grows, a critical question emerges: can recent investment, together with greater national coordination, put the missing pieces in place to translate scientific innovation into therapies that reach patients?
In this context, engagement between European regulatory experts and Ireland’s research and manufacturing community is particularly valuable. Understanding regulatory expectations early in development can help researchers and innovators anticipate challenges and build more effective pathways towards clinical application.

